ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Drug Coming Soon as Pharmaceutical Companies Take Moves in the B7-H3 Immune Target Products Layout
May 23, 2022Based on public information, TAA06 is an independently developed B7-H3-targeted CAR-T therapy of PersonGen. The drug was granted the Orphan Drug Designation (ODD) for treating neuroblastoma by the FDA (Food and Drug Administration) in March of this year. -
Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody
October 21, 2020Y-mAbs Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer..
Pharma Sources Insight January 2025
